Design, synthesis and X-ray crystallographic studies of [7.3.1] and [8.3.1] macrocyclic FKBP-12 ligands

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 4, 1996, Pages 385-390

  Babine, Robert E ^a   Bleckman, T M ^a   Littlefield, Ethel S ^a   Parge, Hans E ^a   Pelletier, L A K ^a   Lewis, Cristina T ^a   French, Judy V ^a   Imbacuan, Michael ^a   Katoh, Susumo ^a   Tatlock, John H ^a   Showalter, Richard E ^a   Villafranca, J Ernest ^a  

^a AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CYCLOPHILIN; MACROCYCLIC COMPOUND; TSUKUBAENOLIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTALLOGRAPHY; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 0029878149     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00032-7     Document Type: Article

References (22)

1. Liu, J.; Farmer, J. D. Jr.; Lane, W. S.; Friedman, J.; Weissman, I.; Schreiber, S. L. Cell 1991, 66, 807.
2. Schreiber, S. L. Cell 1992, 70, 365.
3. Tanaka, H.; Kuroda, A.; Marusawa, H.; Hatanaka, H.; Kino, T.; Hoto, T.; Hashimoto, M.; Taga, T. J. Am. Chem. Soc. 1987, 109, 5031.
4. Van Duyne, G. D.; Standaert, R. F.; Karplus, P. A.; Schreiber, S. L.; Clardy, J. Science 1991, 252, 839.
5. Smith, P. W.; Still, W. C. J. Am. Chem. Soc. 1988, 110, 7917.
6. 2O, reflux, 3 hrs.)
7. (a) Mitsunobu, O. Synthesis 1981, 1.
8. (b) Zibuck, R.; Liverton, N. J.; Smith, A. B. III J. Am. Chem. Soc. 1986, 108, 2451.
9. Kruizinga, W. H.; Kellogg, R. M.; J. Am. Chem. Soc. 1981, 103, 5183.
10. app > 50 μM"). All data were analyzed using the software program KineTic (BioKin, Ltd., Madison, WI).
11. Human recombinant FKBP-12 was purified as described with elimination of the heat treatment step. Standaert, R. F.; Galat, A.; Verdine, G. L.; Schreiber, S. L. Nature 1990, 346, 671.
12. Kofron, J. L.; Kuzmic, P.; Kishore, V.; Colón-Bonilla, E.; Rich, D. H. Biochemistry 1991, 30, 6127.
13. Bartlett, P. A.; Shea, G. T.; Telfer, S. J.; Waterman, S. Spec. Publ. - R. Chem. Soc. 1989, 78, 182.
14. σF) for a model containing 832 protein, 25 ligand and 90 water atoms, with root mean square deviations from ideality of 0.015Å for bond distances and 2.86° on bond angles.
15. Kabalka, G. W.; Shoup, T. M.; Goudgaon, N. M. Tetrahedron Lett. 1989, 30, 1483.
16. Armistead, D. M.; Badia, M. C.; Deininger, D. D.; Duffy, J. P.; Saunders, J. O.; Tung, R. D.; Thompson, J. A.; DeCenzo, M. T.; Futer, O.; Livingston, D. J.; Murco, M. A.; Yamashita, M. M.; Navia, M. A.; Acta. Cryst. 1995, D51, 522.
17. Tatlock, J. H.; Kalish, V. J.; Parge, H. E.; Knighton, D. R.; Showalter, R. E.; Lewis, C. T.; French, J. V.; Villafranca, J. E. Bioorg. Med. Chem. Lett . 1995, 5, 2489.
18. Holt, D. A.; Konialian-Beck, A. L.; Oh, H-J; Yen, H-K.; Rozamus, L. W.; Krog, A. J.; Erhard, K. F.; Ortiz, E.; Levy, M. A.; Brandt, M.; Bossard, M. J.; Luengo, J. I. Bioorg. Med. Chem. Lett. 1994, 4, 315.
19. 19, plus 1% dimethyl sulfoxide as cosolvent and 100 μM FKBP. Compounds were tested for FKBP-dependent inhibition of calcineurin at their maximum solubility. Under these conditions, the apparent inhibition constant for inhibition of human recombinant calcineurin by FKBP-FK506 was 43 nM.
20. Etzkorn, F. A.; Chang, Z.; Stolz, L. A.; Walsh, C. T. Biochemistry 1994, 33, 2380.
21. (a) Griffith, J. P.; Kim, J. L.; Kim, E. E.; Sintchak, M. D.; Thompson, J. A.; Fitzgibbon, M. J.; Fleming, M. A.; Caron, P. R.; Hsiao, K.; Navia, M. A. Cell 1995, 82, 507.
22. (b) Kissinger, C. R.; Parge, H. E.; Knighton, D. R.; Lewis, C. T.; Pelletier, L. A.; Tempczyk, A.; Kalish, V. J.; Tucker, K. D.; Showalter, R. E.; Moomaw, E. W.; Gastinel, L. N.; Habuka, N.; Chen, X.; Maldonado, F.; Barker, J. E.; Bacquet, R.; Villafranca, J. E. Nature, 1995, 378, 641.